Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 1/20 | 0.37 |
| ▸ | PLAU | P00749 | 3/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.33 |
| ▸ | WNT3A | P56704 | 1/20 | 0.33 |
| ▸ | KDM6B | O15054 | 1/20 | 0.33 |
| ▸ | TET3 | O43151 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2653303 | 0.80 | KMT2A (0.40) | AGTR1PLAUESR1ESR2KMT2A | |
| SCHEMBL699210 | 0.80 | AGTR1 (0.43) | AGTR1PLAUESR1ESR2KMT2A | |
| SCHEMBL15881435 | 0.77 | KMT2A (0.35) | AGTR1PLAUESR1ESR2KMT2A | |
| SCHEMBL29142169 | 0.76 | TRIM24 (0.43) | AGTR1PLAUKMT2AMEN1TDP1 | |
| SCHEMBL29791320 | 0.76 | PLAU (0.37) | AGTR1PLAUESR1ESR2TDP1 | |
| SCHEMBL30949901 | 0.76 | MAPT (0.37) | AGTR1PLAUKMT2AMEN1HPGD | |
| SCHEMBL30949909 | 0.76 | MAPT (0.37) | AGTR1PLAUKMT2AMEN1HPGD | |
| SCHEMBL30950066 | 0.74 | PLAU (0.35) | AGTR1PLAUESR1ESR2KMT2A | |
| SCHEMBL30949970 | 0.73 | TBXA2R (0.35) | AGTR1PLAUESR1ESR2KMT2A | |
| SCHEMBL15188908 | 0.72 | GAA (0.46) | ESR1ESR2KMT2AMEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258118-B2 | 4-pyridinone compounds and their use for cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-04 | — | — | US | disclosed |
| US-8124768-B2 | 4-pyridinone compounds and their use for cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-28 | — | — | US | disclosed |
| US-20110034416-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034416-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | DPYD, CDK4, G6PD | AGTR1 1504/4885PLAU 1675/4885ESR1 3400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.